Larazotide-Expressing Microorganisms for Intestinal Barrier Integrity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for intestinal barrier dysfunction and associated diseases, such as Celiac disease and inflammatory bowel conditions, are inadequate, with existing therapies like gluten-free diets being difficult to maintain and having inconsistent effects on paracellular permeability.
Innovation Solution
Engineered microorganisms or bacteriophages expressing the larazotide peptide or its derivatives are used to enhance tight junction integrity in the gastrointestinal epithelium, promoting healthy paracellular permeability by administering them in the form of probiotics or bacteriophages that target specific regions of the GI tract.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gluten-free diet is used to treat Celiac disease, then dietary management is provided, but compliance is difficult to maintain and effects on paracellular permeability are inconsistent
Solution Approach 1:
The patent uses larazotide peptide as an intermediary substance that directly acts on tight junctions to improve intestinal barrier function. Instead of relying on complex dietary management, the peptide serves as a direct pharmacological mediator that targets the specific mechanism of tight junction disruption in Celiac disease, providing more reliable and easier-to-comply treatment
2Reliability
If conventional therapies are used for intestinal barrier dysfunction, then treatment is provided, but effects on paracellular permeability are inconsistent
Solution Approach 1:
The patent employs larazotide peptide which specifically targets and modifies the functional state of tight junction proteins (ZO-1, occludin, claudins) by stabilizing their structure and enhancing their barrier function. This parameter change approach directly addresses the molecular mechanisms of intestinal permeability with a focused therapeutic agent, providing consistent results without complex multi-component regimens
Data Source
AI summary
The present invention provides methods and compositions for maintaining and improving the integrity of gastrointestinal epithelial tight junctions, thereby helping to maintain healthy paracellular permeability of the GI epithelium. The present invention provides methods and compositions for the treatment or prevention of various conditions that are associated with gastrointestinal paracellular permeability, including various autoimmune conditions, inflammatory liver diseases, as well as inflammatory conditions of the large or small intestines.